Only three of ten health care funds available in Finland have pulled in a negative return during the ongoing Coronavirus pandemic, reports Kauppalehti today.
The most successful fund, according to data from Morningstar and based on return since January 2020, is Pictet’s Biotech PUSD fund. The fund’s largest investments are in companies developing new drugs, such as Vertex Pharmaceuticcs and Gilead Sciences, whose drug is expected to help treating Covid-19. The fund's year to day return today stands at 10.6 percent.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for AMWatch has now started
With your free trial you get:
Full access to all locked articles on AMWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.